Merck Discussing Another Drugmaker Buyout -- Buy Or Sell?
Merck & Co., Inc. (MRK) reported solid first-quarter results beating analysts’ estimates for sales and earnings. In addition, given that the company is in talks to acquire another biotech firm to boost its cancer-drug portfolio, would it be wise to buy the stock now? Let’s discuss.
StockNews.com ·
StockNews.com
Benzinga
International Business Times
